Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086159 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37
HOS-086390 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5.).
Ritonavir medicinal product level decreased
Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort
(Hypericum perforatum) due to the risk of
decreased plasma concentrations and reduced
clinical effects of ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 21
HOS-086319 · Präparat HOS-083284
Sedatives/hynoptics
Clorazepate, diazepam, estazolam, Ritonavir co-administration is likely to result in increased plasma concentrations of
flurazepam, oral and parenteral clorazepate, diazepam, estazolam and flurazepam and is therefore contraindicated
midazolam (see section 4.3).
Midazolam is extensively metabolised by CYP3A4. Co-administration with
ritonavir may cause a large increase in the concentration of this benzodiazepine. No
medicinal product interaction study has been performed for the co-administration of
ritonavir with benzodiazepines. Based on data for other CYP3A4 inhibitors, plasma
concentrations of midazolam are expected to be significantly higher when
midazolam is given orally. Therefore, ritonavir should not be co-administered with
orally administered midazolam (see section 4.3), whereas caution should be used
with co-administration of ritonavir and parenteral midazolam. Data from
concomitant use of parenteral midazolam with other protease inhibitors suggest a
possible 3 – 4 fold increase in midazolam plasma levels. If ritonavir is
co-administered with parenteral midazolam, it should be done in an intensive care
unit (ICU) or similar setting which ensures close clinical monitoring and appropriate
medical management in case of respiratory depression and/or prolonged sedation.
Dosage adjustment for midazolam should be considered, especially if more than a
single dose of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) flurazepam (HOS-086166) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage b4a8c845ab5d7e680623aa73248b83ee123be2ef31c29b06379c9aca6376c2f2 · Zeichen 49471–51496 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54
HOS-086482 · Präparat HOS-083284
Sedatives/hypnotics
Clorazepate, diazepam, estazolam, Ritonavir co-administration is likely to result in increased plasma concentrations of
flurazepam, oral and parenteral clorazepate, diazepam, estazolam and flurazepam and is therefore contraindicated (see
midazolam section 4.3).
Midazolam is extensively metabolised by CYP3A4. Co-administration with ritonavir
may cause a large increase in the concentration of this benzodiazepine. No medicinal
product interaction study has been performed for the co-administration of ritonavir with
benzodiazepines. Based on data for other CYP3A4 inhibitors, plasma concentrations of
midazolam are expected to be significantly higher when midazolam is given orally.
Therefore, ritonavir should not be co-administered with orally administered midazolam
(see section 4.3), whereas caution should be used with co-administration of ritonavir and
parenteral midazolam. Data from concomitant use of parenteral midazolam with other
protease inhibitors suggest a possible 3 – 4 fold increase in midazolam plasma levels. If
ritonavir is co-administered with parenteral midazolam, it should be done in an intensive
care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate
medical management in case of respiratory depression and/or prolonged sedation. Dosage
adjustment for midazolam should be considered, especially if more than a single dose of
midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) flurazepam (HOS-086166) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 26dfc2e9db64eee7e9dde0c580824f02a0381c69ed172fbd97b8c76f279a1e77 · Zeichen 51537–53525 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6
HOS-108817 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5).
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43–44
HOS-108990 · Präparat HOS-093083
43
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally
administered midazolam, see section
4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St
John’s wort (Hypericum perforatum)
due to the risk of decreased plasma
concentrations and reduced clinical
effects of lopinavir and ritonavir (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 92a02386fc1a77aef711a4b1e6d441f26b16e78482f67469b16622696dc32d8d · Zeichen 8625–9989 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 78–79
HOS-109064 · Präparat HOS-093083
78
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5)
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and syncope).
See section 4.4 and section 4.5 for
co-administration of sildenafil in patients
with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5fd5fb90c510eab32eaadc8b17bd2236491bc4b4553317338a4ddfd4a5d22f67 · Zeichen 7137–9814 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 20–21
HOS-108905 · Präparat HOS-093083
20
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended
(see section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, and Felodipine, Nifedipine, Clinical monitoring of therapeutic
Nicardipine Nicardipine: and adverse effects is
Concentrations may be increased recommended when these
due to CYP3A inhibition by medicines are concomitantly
lopinavir/ritonavir. administered with Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 07de481e5f74c75a6211a29709c221ad50916e1780e215eb7341382e9a6c287a · Zeichen 41905–45409 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-109016 · Präparat HOS-093083
56
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be used
AUC: ↑ 4-fold with co-administration of Kaletra and
Due to CYP3A inhibition by parenteral midazolam. If Kaletra is
lopinavir/ritonavir co-administered with parenteral
midazolam, it should be done in an
intensive care unit (ICU) or similar
setting which ensures close clinical
monitoring and appropriate medical
management in case of respiratory
depression and/or prolonged sedation.
Dosage adjustment for midazolam
should be considered especially if
more than a single dose of midazolam
is administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when these
due to CYP3A induction by medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage bbdb1518d507ab9bf3037f812d7ca4e3f06d2a449a3a956237657f28f1c80c69 · Zeichen 40688–43969 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91–92
HOS-109092 · Präparat HOS-093083
91
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase
increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) pimozide (HOS-085600) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 703aea6daa39d7a84dcc105bf1c63b26907c5686341c713d7b68e5df123b8727 · Zeichen 40354–44819 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 8
HOS-109373 · Präparat HOS-093187
Injectable anaesthetics
Coadministration of IV parecoxib 40 mg with propofol (CYP2C9 substrate) or midazolam (CYP3A4
substrate) did not affect either the pharmacokinetics (metabolism and exposure) or the
pharmacodynamics (EEG effects, psychomotor tests and waking from sedation) of IV propofol or IV
midazolam. Additionally, coadministration of valdecoxib had no clinically significant effect on the
hepatic or intestinal CYP 3A4-mediated metabolism of orally administered midazolam.
Administration of IV parecoxib 40 mg had no significant effect on the pharmacokinetics of either IV
fentanyl or IV alfentanil (CYP3A4 substrates).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) propofol (HOS-109374) fentanyl (HOS-086196) valdecoxib (HOS-109357) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 662dd1373bd10ba5897ec0ebeead4763dae039c69209cdced5cce7496495d984 · Zeichen 5889–6519 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 24
HOS-109414 · Präparat HOS-093187
Injectable anaesthetics
Coadministration of IV parecoxib 40 mg with propofol (CYP2C9 substrate) or midazolam (CYP3A4
substrate) did not affect either the pharmacokinetics (metabolism and exposure) or the
pharmacodynamics (EEG effects, psychomotor tests and waking from sedation) of IV propofol or IV
midazolam. Additionally, coadministration of valdecoxib had no clinically significant effect on the
hepatic or intestinal CYP 3A4-mediated metabolism of orally administered midazolam.
Administration of IV parecoxib 40 mg had no significant effect on the pharmacokinetics of either IV
fentanyl or IV alfentanil (CYP3A4 substrates).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) propofol (HOS-109374) fentanyl (HOS-086196) valdecoxib (HOS-109357) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage 662dd1373bd10ba5897ec0ebeead4763dae039c69209cdced5cce7496495d984 · Zeichen 5891–6521 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-109470 · Präparat HOS-093201
14
Benzodiazepines
[CYP3A4 substrates] Dose reduction of
Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be
single dose) Midazolam AUC0- 3.7-fold considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 697eefce26706ee5ef3019516b5236b0f8499ab3c01c71de4b77fff7ab733308 · Zeichen 20053–20332 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-109471 · Präparat HOS-093201
Midazolam (7.5 mg oral single In an independent published study,
dose) Midazolam Cmax 3.8-fold
Midazolam AUC0- 10.3-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ea058de56937713aad63e5af948429ce0831fd335800a5885ca5b5049b42a37 · Zeichen 20334–20513 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 45–46
HOS-109544 · Präparat HOS-093201
45
Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any
Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity
(NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose
limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed.
nevirapine)* inhibit the metabolism of NNRTIs.
[CYP3A4 substrates, inhibitors The findings of the effect of
or CYP450 inducers] efavirenz on voriconazole suggest
that the metabolism of
voriconazole may be induced by an
NNRTI.
Antipsychotics
Lurasidone Although not studied, Contraindicated (see section
[CYP3A4 substrate] voriconazole is likely to 4.3)
significantly increase the plasma
concentrations of lurasidone.
Pimozide Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of pimozide 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Anti virals
Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of
[CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir
inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for
loss of voriconazole
effectiveness.
Benzodiazepines
[CYP3A4 substrates] Dose reduction of
Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be
single dose) Midazolam AUC0- 3.7-fold considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage ef43a168f9ab76fd2a9647a23dc50db8759604cb80a4b6eb2684eff57e70dd70 · Zeichen 18658–20764 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 46
HOS-109545 · Präparat HOS-093201
Midazolam (7.5 mg oral single In an independent published study,
dose) Midazolam Cmax 3.8-fold
Midazolam AUC0- 10.3-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ea058de56937713aad63e5af948429ce0831fd335800a5885ca5b5049b42a37 · Zeichen 20766–20945 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 78–79
HOS-109610 · Präparat HOS-093201
78
Benzodiazepines
[CYP3A4 substrates] Dose reduction of
Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be
single dose) Midazolam AUC0- 3.7-fold considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage eb169cc18eb00274eaff06c17c9c5a54a5fc5d10c58f2fc492714eb1cfbf854e · Zeichen 20083–20362 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-109611 · Präparat HOS-093201
Midazolam (7.5 mg oral single In an independent published study,
dose) Midazolam Cmax 3.8-fold
Midazolam AUC0- 10.3-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ea058de56937713aad63e5af948429ce0831fd335800a5885ca5b5049b42a37 · Zeichen 20364–20543 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112044 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide, and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7b7b0f048824fcb784b546989cbc26fbf98af81b02e5d50ce08dc589e2545d88 · Zeichen 636–1122 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.3 · PDF-Seite 40
HOS-112152 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine,
cisapride, pimozide, quinidine, lurasidone, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e442989da36600ebf7f8db27c93ddf7cb3e10a213eeefa38bb99d1990671ccee · Zeichen 495–980 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.